S1P-TREM2轴保护免疫抑制性中性粒细胞免于铁死亡并促进肝细胞癌进展
研究揭示肝细胞癌中肿瘤相关中性粒细胞通过S1P-TREM2-NRF2轴抵抗铁死亡并维持免疫抑制功能。靶向该通路可恢复CD8+ T细胞活性、抑制肿瘤生长并增强抗PD-1疗效。TREM2+ PMN-MDSC富集与预后不良相关。
要点
- TANs通过S1P-TREM2-NRF2轴上调GPX4和SLC7A11抵抗铁死亡。
- TREM2缺失重编程肿瘤免疫微环境并抑制HCC进展。
- 肽类TREM2抑制剂增强抗PD-1免疫治疗疗效。
核心结论
- S1P-TREM2-NRF2轴是维持HCC中中性粒细胞存活和免疫抑制功能的关键代谢-免疫回路,靶向该通路可克服免疫治疗耐药。
研究设计与样本
- 研究采用人HCC样本、多种小鼠HCC模型、转录组和脂质组分析、遗传功能缺失系统及治疗干预,系统评估TANs的铁死亡敏感性、脂质代谢重编程和免疫学后果。
主要发现
- 人HCC和小鼠模型中的TANs较外周中性粒细胞表现出明显的脂质积累和氧化应激。
- 多组学分析显示TANs富集脂质结合基因程序,并向鞘脂和不饱和脂肪酸代谢重编程。
- TREM2是选择性表达于TANs的关键脂质感应受体,其功能缺失重编程肿瘤免疫微环境、恢复CD8+ T细胞活性并抑制HCC进展。
- 肿瘤来源S1P激活TREM2,触发NRF2介导的GPX4和SLC7A11转录,促进铁死亡抵抗。
- TREM2表达由GM-CSF-STAT3信号转录诱导,遗传缺失TREM2、CRISPR/Cas9敲除肿瘤细胞SPHK1/2或药理学抑制S1P合成可破坏该保护性回路。
临床怎么用
- 靶向TREM2或S1P合成可增敏TANs铁死亡并限制肿瘤生长,肽类TREM2抑制剂可增强抗PD-1免疫治疗疗效。
- TREM2+ PMN-MDSCs富集与SPHK1/2表达、T细胞功能障碍及患者不良预后相关,或可作为预后标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neutrophils are increasingly recognised as immunosuppressive drivers of hepatocellular carcinoma (HCC), yet their persistence in the oxidative, lipid-rich tumour microenvironment remains poorly understood. OBJECTIVE: To elucidate the metabolic and molecular programmes that enable tumour-associated neutrophils (TANs) to resist ferroptosis and sustain immunosuppression in HCC. DESIGN: We employed human HCC samples, multiple murine HCC models, transcriptomic and lipidomic profiling, genetic loss-of-function systems and therapeutic interventions. Ferroptosis sensitivity, lipid metabolic rewiring and immunological consequences of TANs were systematically evaluated across models and validated in patient datasets and biospecimens. RESULTS: TANs in human HCC and mouse models exhibit pronounced lipid accumulation and oxidative stress compared with peripheral neutrophils. Multi-omic profiling revealed that TANs are enriched for lipid-binding gene programmes and undergo rewiring towards sphingolipid and unsaturated fatty acid metabolism. We identified triggering receptor expressed on myeloid cells 2 (TREM2) as a key lipid-sensing receptor selectively expressed in TANs. Functional deletion of TREM2 reprogrammed the tumour immune microenvironment, restoring CD8+ T cell activity and suppressing HCC progression. Mechanistically, tumour-derived sphingosine-1-phosphate (S1P) activates TREM2, triggering nuclear factor erythroid 2-related factor 2 (NRF2)-mediated transcription of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), thereby promoting ferroptosis resistance. TREM2 expression is transcriptionally induced by granulocyte-macrophage colony-stimulating factor-signal transducer and activator of transcription 3 (GM-CSF-STAT3) signalling. Genetic deletion of TREM2, clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9)-mediated knockout of sphingosine kinase 1/2 (SPHK1/2) in tumour cells, or pharmacological inhibition of S1P synthesis disrupts this protective lipid-immune circuit, sensitises TANs to ferroptosis and restricts tumour growth. Therapeutically, a peptide-based TREM2 inhibitor reprogrammes TANs, restores CD8+ T cell function and enhances anti-programmed cell death protein 1 (PD-1) immunotherapy efficacy. Clinically, TREM2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are enriched in HCC tumours, correlate with SPHK1/2 expression and T cell dysfunction and associate with poor patient prognosis. CONCLUSION: Our study uncovers the S1P-TREM2-NRF2 axis as a critical metabolic-immune circuit that preserves neutrophil survival and immunosuppressive function in HCC. Targeting this lipid-dependent ferroptosis resistance pathway offers a promising therapeutic strategy to overcome immunotherapy resistance in liver cancer.
引用
- Ma J, Wu T, Chen D, et al. S1P-TREM2 axis protects immunosuppressive neutrophils from ferroptosis to promote tumour progression in hepatocellular carcinoma. Gut. 2026. PMID: 42705697. doi:10.1136/gutjnl-2025-337414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。